UP!
 |
|
|
Type
|
Public |
|---|---|
| Founded | 2002 (2002) |
| Founder | Eckard Weber |
| Headquarters | La Jolla, California, U.S. |
| Website | www |
Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity. The company is based in La Jolla, California and was established by Eckard Weber in 2002. As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX. The company has a single product, Contrave, approved for use in the United States in 2014. The launch of Contrave was conducted through a sales force of 900. Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.
| 2016-03-16 | Lower Price Target | Leerink Swann | Market Perform | $2.00 to $1.00 |
| 2016-03-16 | Downgrade | Piper Jaffray | Overweight to Neutral | $5.00 to $2.00 |
| 2016-03-16 | Downgrade | JMP Securities | Outperform to Market Perform | |
| 2016-03-16 | Downgrade | Piper Jaffray Cos. | Overweight to Neutral | $5.00 to $2.00 |
| 2016-02-29 | Lower Price Target | JMP Securities | $7.00 to $2.00 | |
| 2016-02-29 | Lower Price Target | Piper Jaffray | Overweight | $11.00 to $5.00 |
| 2016-02-29 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | |
| 2016-02-29 | Downgrade | RBC Capital | Outperform to Sector Perform | $5.00 to $1.00 |
| 2016-02-29 | Downgrade | Royal Bank Of Canada | Outperform to Sector Perform | $5.00 to $1.00 |
| 2016-02-23 | Downgrade | Leerink Swann | Outperform to Market Perform | $4.50 to $2.00 |
| 2016-02-23 | Downgrade | Leerink Partner | Outperform to Market Perform | |
| 2015-12-16 | Downgrade | WallachBeth Capital | Buy to Hold | |
| 2015-12-12 | Reiterated Rating | Bank of America | Sell | |
| 2015-12-12 | Reiterated Rating | Bank of America Corp. | Sell | |
| 2015-12-11 | Initiated Coverage | Bank of America | Underperform | $2.00 |
| 2015-12-04 | Downgrade | Wells Fargo | Outperform to Market Perform | |
| 2015-12-04 | Downgrade | Wells Fargo & Co. | Outperform to Market Perform | |
| 2015-11-07 | Reiterated Rating | Leerink Swann | Buy | |
| 2015-11-06 | Reiterated Rating | Leerink Swann | Outperform | $8.00 to $4.50 |
| 2015-11-06 | Lower Price Target | JMP Securities | Market Outperform | $7.00 |
| 2015-11-06 | Lower Price Target | RBC Capital | Outperform | $9.00 to $5.00 |
| 2015-10-06 | Lower Price Target | Piper Jaffray | Overweight | $21.00 to $11.00 |
| 2015-09-15 | Reiterated Rating | RBC Capital | Outperform | $14.00 to $9.00 |
| 2015-08-10 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $8.00 |
| 2015-08-06 | Reiterated Rating | Piper Jaffray | Buy | $17.00 to $21.00 |
| 2015-05-14 | Reiterated Rating | RBC Capital | Outperform | $14.00 |
| 2015-05-14 | Reiterated Rating | Leerink Swann | Outperform | $11.00 |
| 2015-04-22 | Set Price Target | Bank of America | Buy | $13.00 |
| 2015-03-27 | Boost Price Target | RBC Capital | Buy | $10.00 to $14.00 |
| 2015-03-06 | Reiterated Rating | RBC Capital | Buy | |
| 2015-03-04 | Boost Price Target | Leerink Swann | Outperform | $8.00 to $11.00 |
| 2015-03-03 | Boost Price Target | Piper Jaffray | Overweight | $16.00 to $26.00 |
| 2015-02-24 | Reiterated Rating | Leerink Swann | Outperform | $8.00 |
| 2015-01-22 | Initiated Coverage | RBC Capital | Outperform | $10.00 |
| 2015-01-02 | Reiterated Rating | Bank of America | Buy | $9.00 to $10.00 |
| 2014-11-10 | Reiterated Rating | Wells Fargo & Co. | Outperform | |
| 2014-11-10 | Reiterated Rating | Wells Fargo | Outperform | |
| 2014-09-11 | Boost Price Target | Wells Fargo & Co. | $15.00 | |
| 2014-09-11 | Boost Price Target | Wells Fargo | $15.00 | |
| 2014-09-04 | Initiated Coverage | Credit Suisse | Outperform | $10.00 |
| 2014-09-04 | Initiated Coverage | Credit Suisse Group AG | Outperform | $10.00 |
| 2014-04-24 | Initiated Coverage | Wells Fargo & Co. | Outperform | |
| 2014-04-24 | Initiated Coverage | Wells Fargo | Outperform | |
| 2014-01-10 | Initiated | WallachBeth | Buy | $9 |
| 2014-01-10 | Initiated Coverage | WallachBeth Capital | Buy | $9.00 |
| 2013-11-27 | Reiterated Rating | JPMorgan Chase & Co. | Overweight to Positive | $12.00 |
| 2013-11-26 | Lower Price Target | Credit Suisse | Outperform | $11.00 to $10.00 |
| 2013-10-04 | Reiterated Rating | Jefferies Group | Hold | $7.00 |
| 2013-10-03 | Initiated Coverage | Cowen and Company | Outperform to Outperform | $10.00 |
| 2011-09-21 | Upgrade | JMP Securities | Mkt Perform to Mkt Outperform | $5 |
| 2011-02-01 | Downgrade | JMP Securities | Mkt Outperform to Mkt Perform | |
| 2011-02-01 | Downgrade | Canaccord Genuity | Buy to Hold | |
| 2010-12-03 | Downgrade | Rodman & Renshaw | Mkt Perform to Mkt Underperform | |
| 2010-02-02 | Initiated | Jefferies & Co | Buy | $12 |
| 2009-03-13 | Reiterated | Lazard Capital Mkts | Buy | $13 to $10 |
| 2008-04-03 | Initiated | Cowen & Co | Outperform | |
| 2008-02-06 | Initiated | Lazard Capital | Buy | |
| 2008-02-04 | Reiterated | Canaccord Adams | Buy | $29 to $32 |
| 2008-01-03 | Initiated | JP Morgan | Overweight | |
| 2007-10-03 | Upgrade | JMP Securities | Mkt Outperform to Strong Buy | $26 |
| 2007-06-07 | Initiated | JP Morgan | Overweight | |
| 2007-06-06 | Initiated | JMP Securities | Mkt Outperform | $26 |
| 2016-03-16 | Lower Price Target | Leerink Swann | Market Perform | $2.00 to $1.00 |
| 2016-03-16 | Downgrade | Piper Jaffray | Overweight to Neutral | $5.00 to $2.00 |
| 2016-03-16 | Downgrade | JMP Securities | Outperform to Market Perform | |
| 2016-03-16 | Downgrade | Piper Jaffray Cos. | Overweight to Neutral | $5.00 to $2.00 |
| 2016-02-29 | Lower Price Target | JMP Securities | $7.00 to $2.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In OREX 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
UM